The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
WitzigT.E., WhiteC.A., WisemanG.A.Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma.J Clin Oncol.1999; 17(12): 3793–803.
2.
WisemanG.A., WhiteC.A., SparksR.B.Biodistibution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.Crit Rev Oncol/Hematol.2001; 39(1-2): 181–94.
3.
WitzigT.E., GordonL.I., CabanillasF.Randomized controlled trial of Yttrium-90 labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.J Clin Oncol.2002; 20(10): 2453–63.
4.
WisemanG.A., GordonL.I., MultaniP.S.Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma in mild thrombocytopenia: A phase II multicenter trial.Blood.2002; 99(12): 4336–42.
AnsellS.M., RistowK.M., HabermannT.M.Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with Yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.J Clin Oncol.2002; 20(18): 3885–90.
7.
WisemanG.A., LeighB., ErwinW.D.Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin's lymphoma.Cancer.2002; 94(suppl 1); 1349–57.
8.
WitzigT.E., FlinnI.W., GordonL.I.Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.J Clin Oncol.2002; 20(15): 3262–9.
9.
WitzigT.E., WhiteC.A., GordonL.I.Safety of Yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma.J Clin Oncol.2003; 21(7): 1263–70.
KaminskiM.S., EstesJ., ZasandnyK.R.Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: Updated results from long-term follow-up of the University of Michigan experience.Blood.2000; 96(17): 1259–66.
12.
PressO.W., EaryJ.F., AppelbaumF.R.: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.N Engl J Med.1993; 329(17): 1219–24.
13.
Bexxar (tositumomab and 131I tositumomab) [product information].Seattle, WA: Corixa Corp.; Philadelphia, PA: GlaxoSmithKline; June 2003.
14.
VoseJ.M., WahlR.L., SalehM.Multicenter phase II study of iodine 131I tositumomab for chemotherapy-relapsed/refractory transformed low-grade and b-cell non-Hodgkin's lymphomas.J Clin Oncol.2000; 18(6): 1316–23.
15.
KaminskiM.S., ZelenetzA.D., PressO.W.Pivotal study of iodine 131I tositumomab for chemotherapy refractory low-grade or transformed non-Hodgkin's lymphomas.J Clin Oncol.2001(19): 3918–28.
16.
HarwoodS.J., GibbonsL.K., GoldnerP.J.Outpatient radioimmunotherapy with Bexxar: Closed, clean air reservoir minimizes personnel radiation exposure.Cancer.2002; 94(suppl 1): 1358–82.
17.
PressO.W., UngerJ.M., BrazielR.M.A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Southwest Oncology Group Protocol S9911.Blood.2003; 102(5): 1606–12.
